Gotham Asset Management LLC Trims Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Gotham Asset Management LLC lowered its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 7.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 150,120 shares of the medical research company's stock after selling 12,302 shares during the quarter. Gotham Asset Management LLC owned about 0.08% of Exact Sciences worth $8,435,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Asset Planning Inc acquired a new stake in Exact Sciences during the fourth quarter worth about $40,000. AlphaQuest LLC increased its position in shares of Exact Sciences by 22,825.0% during the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after acquiring an additional 913 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Exact Sciences during the fourth quarter valued at about $66,000. Ostrum Asset Management increased its position in shares of Exact Sciences by 28.4% during the fourth quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock valued at $134,000 after acquiring an additional 527 shares during the last quarter. Finally, Kieckhefer Group LLC acquired a new stake in shares of Exact Sciences during the fourth quarter valued at about $188,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Royal Bank of Canada raised their price objective on shares of Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Piper Sandler decreased their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Evercore ISI boosted their price target on shares of Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Finally, Scotiabank boosted their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Exact Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $70.90.

Exact Sciences Trading Up 0.4%

EXAS traded up $0.25 on Friday, reaching $56.42. 3,197,591 shares of the company's stock were exchanged, compared to its average volume of 2,606,218. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences Co. has a twelve month low of $39.97 and a twelve month high of $72.83. The company's 50 day moving average is $46.16 and its 200-day moving average is $52.41. The company has a market cap of $10.64 billion, a price-to-earnings ratio of -10.13 and a beta of 0.92.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. During the same quarter last year, the company earned ($0.60) earnings per share. Exact Sciences's revenue for the quarter was up 10.9% on a year-over-year basis. Equities analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.